Navigation Links
Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
Date:12/2/2007

Top-line data expected in early 2008

TARRYTOWN, N.Y., Dec. 3 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has completed patient enrollment in the Phase IIb "Neuracept" trial for EpiCept(TM) NP-1 cream. EpiCept NP-1 is a patented topical cream formulation of two FDA- approved drugs, 4% amitriptyline and 2% ketamine, and is intended to provide long-term relief from the pain of peripheral neuropathies.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

This Phase IIb trial compares the active ingredients in NP-1 against placebo in patients suffering from diabetic peripheral neuropathy (DPN), the most common form of neuropathic pain. Only two medications are currently available in the United States for the treatment of DPN. The four-week, 200- patient trial is intended to confirm and expand upon earlier work that provided a preliminary efficacy signal in this type of neuropathic pain. The primary endpoint for the Phase IIb trial is the difference between active and placebo changes in pain intensity from baseline compared to the average over the last seven days of treatment.

"We are pleased to have reached another key clinical milestone that we established for 2007, and to have advanced another one of our product candidates," stated Jack Talley, President and Chief Executive Officer of EpiCept. "We believe NP-1 holds the largest market potential of the pain candidates in our portfolio. Treatment of neuropathic pain is a billion dollar opportunity. We believe that NP-1 has the potential to become a new and efficacious topical treatment without the inherent systemic side effects of alternative treatments for the 15 million Americans who suffer from peripheral neuropathies. We expect to report top-line results from this trial in early 2008."

In addition to t
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
2. Comparison of obstetric outcomes between on-call and patients own obstetricians
3. Vision restoration therapy shown to improve brain activity in brain injured patients
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
6. Restricting Blood Flow May Help Heart Bypass Patients
7. Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer
8. Study provides hope that some transplant patients could live free of antirejection drugs
9. Study provides hope that some transplant patients could live free of anti-rejection drugs
10. Longer ambulance journeys boost death risk for seriously ill patients
11. Expenses Overshadow Optimism for Kidney Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... According to the market research report ... Technology (ICS, MES, ERP, ITS), Field Devices, Products ... (Process, Discrete) - Global Forecast & Analysis to ... market is expected to reach $6.99 Billion at ... 70 market data Tables and 96 Figures spread ...
(Date:7/30/2014)... 2014 “Today, we have said ¡Basta! ... are being promoted to our children and our families. ... the beverage industry to put the health of people ... Jane L. Delgado, President and CEO of the National ... Sugar-Sweetened Beverage Tax (SWEET) Act by Congresswoman Rosa L. ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 “North America ... market data on the North America Contrast Media Injectors ... dollars, and volume (in units) and average price data ...     CT Injectors ,     Interventional Cardiology/Angio Injectors and MRI ... contrast agent) is a substance used to enhance the ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The Dr. ... Spohn Health, recently announced the proposed naming of the ... Dr. Hector P. Garcia Family Health Center. , The ... health care services, including comprehensive chronic disease management programs, ... also be a pioneering medical home model center. , ...
(Date:7/30/2014)... Decene is an alkene with ... ten carbon atoms with one double bond. 1-Decene ... It can be used as a co-monomer in ... epoxides, amines, oxo alcohols, synthetic lubricants, synthetic fatty ... will receive 10% customization on this report. , ...
Breaking Medicine News(10 mins):Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 2Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 3Health News:Contrast Media Injectors Market in North America (US, Canada, Mexico) to 2020 Report Available at MarketOptimizer.org 4Health News:Dr. Hector P Garcia Memorial Foundation Supports New Health Care Facility 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4
... A study by researchers at UC Davis has found that ... to produce autoantibodies to the brains of their developing fetuses ... risk of later being diagnosed with autism. The finding ... in the development of the neurodevelopmental disorder among some children ...
... Canadian Journal of Cardiology ( www.onlinecjc.ca ) ... imaging methods. This study is important for patients worried ... heart. X-ray based methods have greatly improved the diagnosis ... of radiation exposure. New imaging methods offer ...
... Serena Gordon HealthDay Reporter , TUESDAY, Oct. ... the way that parts of kidney dialysis machines are ... A recently developed sterilization method called electron ... platelets in the blood of dialysis patients, according to ...
... online Oct. 18 in the Journal of the National ... the idea that the immune system,s response to allergies may ... with somewhat elevated blood levels of immunoglobulin E (IgE), antibodies ... significantly less likely to develop gliomas, and those who did ...
... Ind. -- A new study by researchers at Indiana University ... men surprisingly diverse, suggesting that a broader, less disease-focused perspective ... addressing the sexual health of gay and bisexual men. ... Journal of Sexual Medicine, tapped the largest sample ...
... population will nearly double by 2050, according to a ... exists as to who will care for them as ... but those caregiving roles are becoming blurred as more ... previous decades. Now, University of Missouri researchers have found ...
Cached Medicine News:Health News:Genetic variant and autoantibodies linked to having a child with autism 2Health News:Genetic variant and autoantibodies linked to having a child with autism 3Health News:Genetic variant and autoantibodies linked to having a child with autism 4Health News:Study Links New Dialysis Technology to Rise in Bleeding Risk 2Health News:Study Links New Dialysis Technology to Rise in Bleeding Risk 3Health News:More evidence that allergies may help in fighting brain tumors 2Health News:New study finds gay and bisexual men have varied sexual repertoires 2Health News:New study finds gay and bisexual men have varied sexual repertoires 3Health News:Relationships more important than genetic ties when deciding who cares for aging family, study finds 2
(Date:7/30/2014)... and KISSING, Germany , July 30, ... a single use and computer-assisted ("robotic") colonoscopy system, today ... a worldwide recognized medical device executive, as a new ... Shamir is a highly respected global visionary in the ... served as President and Chief Executive Officer at Given ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... VEGAS , July 30, 2014  DigiPath, Inc. ... that is expanding into the cannabis testing and education ... in its business and affairs not previously disclosed or, ... the recent unusual market action. "We have ... over the last three trading days," said Steve ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2
... , , SAN DIEGO , Jan. 15 ... entry of a settlement agreement which will resolve the consolidated securities ... Master File No: 3:09-cv-00921-LAB-WMC. The defendants have agreed to pay ... the company has agreed to issue to the plaintiffs, class a ...
... , , , , , , ... Jan. 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ("China ... a,leading fully integrated pharmaceutical company developing and producing,over-the-counter drugs in ... the Company has relocated its headquarters to its new buildings,in ...
Cached Medicine Technology:Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 2Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 3Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit 4China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 2China Sky One Medical, Inc. Completes and Moves into New Corporate Headquarters 3
... AFO is designed to treat or help ... immobility such as hip displasia, foot drop, ... A comfortable Kodel lining provides a comfortable ... anti-rotation bar is easily rotated and locked ...
... RCAI provides adjustable static stretch of the ... as diminished foot and ankle range of ... straps attached to the sides of the ... be controlled, as needed, in the desired ...
... Splint is indicated for the treatment of ... economical and easy to apply. The splint ... dorsiflexion, limiting nightly contractures and tightening of ... feature permits flexibility in the treatment of ...
This popular post op shoe provides quality care at an outstanding value. The semi-rigid outsole provides stability and minimizes flexure....
Medicine Products: